Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...
A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...
In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...
The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...
A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...
The DISCUS trial demonstrated improved QOL with 3 cycles of chemotherapy compared to 6 cycles in advanced urothelial cancer patients. Both treatment arms showed similar overall survival and ...
Regarding efficacy, the phase 1 trial showed impressive objective response rates (ORR), approaching 70%. Typical PRRT alone ...
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...
Park says patient-specific factors that influence his treatment selection include the presence of liver disease, ...
The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback